Prediction of Long‐Term Survival in Chronic Heart Failure by Multiple Biomarker Assessment: A 15‐Year Prospective Follow‐Up Study
Open Access
- 18 November 2010
- journal article
- research article
- Published by Wiley in Clinical Cardiology
- Vol. 33 (11) , 700-707
Abstract
Background: In chronic heart failure (CHF), several plasma biomarkers identify subjects at risk of death over the midterm. However, their long-term predictive value in the context of other candidate predictors has never been assessed. This information may prove valuable in the management of a chronic disease with a long natural history, as CHF is today. Hypothesis: We aimed to assess the very-long-term prognostic power of a set of biomarkers to identify CHF patients at highest risk for all-cause mortality. Methods: A group of 106 consecutive outpatients with CHF (85 male and 21 female, median age 56 y) was followed for 15 years. Echocardiographic tracings and blood samples were collected at study entry to evaluate cardiac function, plasma atrial natriuretic peptide (ANP), aldosterone, and erythropoietin, and plasma renin activity. The relationships between biomarkers, clinical and echocardiographic variables, and mortality were assessed. Results: After 15 years, 86 of the 106 patients (81%) had died. Multivariate analysis showed that ANP was the best independent predictor of survival over several clinical, echocardiographic, and humoral variables (hazard ratio: 5.62, 95% confidence interval: 3.37–9.39, P < 0.001 for plasma levels < median value of 71 pg/mL). Plasma renin activity and erythropoietin provided prognostic information in univariate analysis, but lost their predictive power when adjusted for covariates. Conclusions: The present study represents the longest available follow-up of patients with CHF evaluating the prognostic power of multiple biomarkers. It shows that a simple assessment of plasma ANP levels is the strongest long-term predictor of death in all stages of heart failure. Copyright © 2010 Wiley Periodicals, Inc. This work was supported by a grant from MIUR 2001068248. The authors have no other funding, financial relationships, or conflicts of interest to disclose.Keywords
This publication has 38 references indexed in Scilit:
- Secular trends of heart failure among US male physiciansAmerican Heart Journal, 2007
- Usefulness of Temporal Changes in Neurohormones as Markers of Ventricular Remodeling and Prognosis in Patients With Left Ventricular Systolic Dysfunction and Heart Failure Receiving Either Candesartan or Enalapril or BothThe American Journal of Cardiology, 2005
- Temporal trends on the risk of arrhythmic vs. non-arrhythmic deaths in high-risk patients after myocardial infarction: a combined analysis from multicentre trialsEuropean Heart Journal, 2005
- Neurohormonal risk stratification for sudden death and death owing to progressive heart failure in chronic heart failureEuropean Journal of Clinical Investigation, 2005
- Trends in Heart Failure Incidence and Survival in a Community-Based PopulationJAMA, 2004
- Prophylactic Implantation of a Defibrillator in Patients with Myocardial Infarction and Reduced Ejection FractionNew England Journal of Medicine, 2002
- Hormones and Hemodynamics in Heart FailureNew England Journal of Medicine, 1999
- Blood levels of erythropoietin in congestive heart failure and correlation with clinical, hemodynamic, and hormonal profilesThe American Journal of Cardiology, 1994
- Prognostic significance of N-terminal pro-atrial natriuretic factor (1-98) in acute myocardial infarction: comparison with atrial natriuretic factor (99-126) and clinical evaluation.Heart, 1993
- Cardiac effects of atrial natriuretic peptide in subjects with normal left ventricular functionThe American Journal of Cardiology, 1989